ImmunityBio Reports Preliminary Q1 2026 Revenue Growth and Clinical Updates for ANKTIVA
On April 9, 2026, ImmunityBio, Inc. announced preliminary unaudited financial results for the first quarter ended March 31, 2026. The company reported record preliminary net product revenue of approximately $44.2 million, representing a 168% increase year-over-year and a 15% sequential increase over Q4 2025. This growth is driven by the continued adoption of ANKTIVA by U.S. urologists. ImmunityBio ended the quarter with approximately $380.9 million in cash, cash equivalents, and marketable securities. On the clinical front, the company announced that its pivotal BCG-naΓ―ve NMIBC CIS trial (QUILT-2.005) is now fully enrolled, with the Independent Data Monitoring Committee confirming adequate statistical power. A supplemental Biologics License Application (sBLA) for this indication is on track for submission in 2026. Additionally, the NCCN Clinical Practice Guidelines were updated in March 2026 to include ANKTIVA plus BCG for certain BCG-unresponsive NMIBC patients. ANKTIVA is currently approved or authorized in five regulatory jurisdictions covering approximately 34 countries.